The American Society of Clinical Oncology (ASCO) recently published a guideline reinforcing the longstanding recommendation that all women diagnosed with epithelial ovarian cancer (EOC) be offered genetic testing for hereditary ovarian cancer genes.
Many of these women (>15%) have an inherited mutation, most commonly BRCA1 or BRCA2. Identifying BRCA1/2 mutations may help guide cancer treatment.
Check out a commentary about the original article at https://www.cancertherapyadvisor.com/home/cancer-topics/gynecologic-cancer/ovarian-cancer-asco-guideline-germline-testing-recommendation-all-women/
Check out NCCN guidelines, which have recommended genetic testing for all ovarian cancer patients https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf